news[Former Asklep] ASKLEP joins Medidata Partner Program to Expand Clinical Trial Services in Asia Pacific

*Articles from the former Asklep

Asklep Inc. (Headquarters: 3-1-3 Higashi Ikebukuro, Toshima-ku, Tokyo, Japan, Representative Director and President: Hiroshi Ichikawa) has joined the Medidata Partner Program offered by Medidata Solutions Inc. (NASDAQ:MDSO). Our in-house developed EDC system solutions have successfully been providing consistently excellent service from system architecture to operations. Joining the Mediata Partner Program will enable us to better accommodate the specific needs of every sponsor and project.

Asklep is committed to providing high quality and unique solutions for drug lifecycle management through our Vision “ACTION for ACTS (Asian Clinical Trials and Solutions)”. We are determined to become “A HUB for Pharmaceutical Intelligence” and believe the partnership with Medidata Solutions with their broad experience in the region, will enhance this role.

Medidata Solutions, Inc. press release

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

For further information, please contact

inquiry
INTAGE Healthcare Inc.

SHARE

facebooktwitter